Month: September 2026

HONG KONG, Sept. 24, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today announced a strategic partnership with HashBeaver, designating it as a cloud retail and distribution platform for the Company’s Finnish green AI compute center. This collaboration marks the expansion of the Finnish project’s service scope, supplementing its traditional enterprise client base by integrating with the global Web3 and decentralized physical infrastructure network (“DePIN”) ecosystems.

Establishing a Compute Gateway and Token-Based Settlement

Within this partnership, HashBeaver will serve as a compute gateway for 3 E Network’s Finnish AI compute center. While traditional compute leasing often involves complex underlying environment configurations, HashBeaver utilizes its cloud APIs with the aim of transforming the high-density GPU bare-metal clusters within 3 E Network’s Finnish facility into an elastic compute pool. Additionally, the gateway supports Web3 payment protocols, allowing global AI developers, decentralized communities, and startup teams to utilize supported digital assets, including certain stablecoins and utility tokens. Through on-chain smart contracts, users can authenticate compute usage and conduct on-demand settlement. This token settlement mechanism is designed to connect traditional physical compute infrastructure with the global decentralized developer ecosystem.

Optimizing Global Channels and Broadening Long-Tail Market Reach

By integrating token-based payment mechanisms, this collaboration is expected to broaden the distribution channels and improve the commercial utilization of the Company’s Finnish project, focusing on two primary areas:

• Reducing Cross-Border Payment Friction: Traditional fiat payment systems may create payment and settlement friction for international developers seeking access to compute resources. The token settlement system utilizes blockchain networks to facilitate cross-border payment and settlement, enabling developers globally to access the Finnish AI compute center’s capacity with greater flexibility and potentially lower transaction costs.
• Enhancing Asset Liquidity and Market Reach: Leveraging on-chain smart contracts and the micro-payment attributes of tokens, large-scale GPU clusters can be structured as compute-backed real-world assets (compute “RWA”), supporting millisecond-level metering and flexible resource allocation. This model allows small-to-medium AI laboratories to procure capacity precisely based on specific task durations. Transitioning a portion of capital expenditures into operational expenditures supports broader coverage of long-tail market demand and aims to optimize server utilization rates, thereby supporting the overall return on investment of the underlying hardware.

Highlighting Physical Infrastructure Value and Establishing a Compliance Framework

Despite the integration with decentralized networks, the foundation of this channel remains reliant on 3 E Network’s physical infrastructure. End-users, whether large enterprise clients via fiat channels or Web3 token retail clients accessing through the HashBeaver gateway, utilize the green, low-carbon, high-density compute power provided by 3 E Network’s Finnish AI compute center. Amidst increasingly stringent industry standards regarding the carbon footprint of compute operations, ESG-compliant green compute is expected to maintain consistent market demand.

Furthermore, this “B2B2C” operational model establishes a structured compliance framework for 3 E Network. Under this arrangement, the Company maintains its role as an infrastructure provider, collecting fiat (or compliant stablecoin) leasing revenue directly from HashBeaver. Operations related to retail-facing token payment integration, decentralized network distribution, and potential token volatility risks are independently managed and assumed by the HashBeaver platform. This structure is intended to delineate the respective operational responsibilities of 3 E Network and HashBeaver, with HashBeaver responsible for retail-facing token payment integration and decentralized network distribution.

Management Commentary

“In addition to developing green computing infrastructure, establishing flexible and globally accessible settlement channels is a vital component in enhancing the commercial value of our project,” stated Dr. Tingjun Yang, Chief Executive Officer of 3 E Network. “Our collaboration with HashBeaver is a key strategic initiative. The supported token payment methods can make our compute resources more accessible to the decentralized developer ecosystem. Combining green real-world assets with Web3 payment networks supports the diversification of our monetization pathways, broadens our potential customer base, and strengthens our competitive position in the next-generation AI infrastructure sector.”

About 3 E Network Technology Group Limited
3 E Network Technology Group Limited is a business-to-business (“B2B”) information technology (“IT”) business solutions provider committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider. It upholds the industry consensus of “AI and energy symbiosis” and has a strong vision in the field of energy investment. The Company’s business comprises two main portfolios: the data center operation services portfolio and the software development portfolio. For more information, please visit the Company’s website at https://3emask.com/.

About HashBeaver
HashBeaver is a cloud platform that connects physical AI computing infrastructure with global users. By virtualizing large-scale physical clusters into elastic cloud resources, it serves as a highly efficient compute gateway. Powered by smart contracts and token settlement, HashBeaver provides flexible, pay-as-you-go AI compute services to developers, startups, and decentralized communities worldwide. For more information, please visit https://hashbeaver.com/.

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect the Company’s future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

3 E Network Technology Group Limited
Investor Relations Department
Email: ird@3emask.com
Website: https://3emask.com/

Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities

Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that Prof. Dan T. Major has joined the Scientific Advisory Board (“SAB”) of its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”).

Prof. Major will provide scientific advice to MitoCareX on the evaluation and application of computational chemistry, and in silico approaches relevant to drug- discovery. His appointment supports MitoCareX’s efforts to expand internal computational capabilities intended to inform the prioritization of discovery programs and opportunities.

Prof. Major is a Professor of Chemistry at Bar-Ilan University. His research interests include computational chemistry, computational biochemistry, in silico drug development, enzyme design, molecular simulations and cheminformatics. His research group develops and applies computational methods and software tools to study chemical and biological systems.

“We are pleased to welcome Prof. Dan T. Major to MitoCareX’s Scientific Advisory Board,” said Dr. Alon Silberman, Chief Executive Officer of MitoCareX. “We believe that his experience in in silico modeling and drug discovery is highly relevant as we expand the internal scientific capabilities supporting our discovery programs. Prof. Major’s perspective will help guide our evaluation of computational approaches across selected discovery priorities.”

MitoCareX utilizes computationally guided approaches for drug discovery. The Company is evaluating methods intended to support the scientific assessment and prioritization of selected discovery programs. The Company has previously initiated a drug-discovery collaboration with Boltz, an AI research lab that focuses on biomolecular foundation models and drug discovery workflows.

About MitoCareX Bio Ltd.
MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/

About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated contributions of Prof. Dan T. Major, D, MitoCareX’s efforts to expand internal computational capabilities intended to inform the prioritization of discovery programs and opportunities and how the Company is evaluating methods intended to support the scientific assessment and prioritization of selected discovery programs. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

Nevada air permit secured and facility work completed at Eagle Springs

WOODS CROSS, Utah, Sept. 24, 2026 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or the “Company”), an energy infrastructure company focused on domestic refining and resource development, today announced that it has received an air permit from the Nevada Division of Environmental Protection and has restarted operations at its Eagle Springs Refinery near Ely, Nevada. The refinery is operated by the Company’s wholly owned subsidiary, Foreland Refining Corporation.

In preparation for the restart, Sky Quarry completed approximately $300,000 in repairs and upgrades identified through a TAR360 assessment commissioned in 2025. Eagle Springs has a stated nameplate capacity of approximately 5,000 barrels of crude oil per day. The Company has approximately 15,000 barrels of crude oil inventory on hand and expects additional supply as operations progress.

“Receiving this permit and restarting Nevada’s only crude oil refinery is a major step for Sky Quarry,” said Marcus Laun, Interim Chief Executive Officer of Sky Quarry. “Nevada has relied on fuel refined elsewhere for too long. Our job now is to ramp Eagle Springs toward its full operating potential and make Nevada-refined products a more meaningful part of the region’s supply.”

Sky Quarry presented at a Nevada Fuel Resiliency Committee meeting earlier in 2026 and intends to remain engaged as the state considers fuel supply and infrastructure initiatives.

As previously announced, the Company also supports proposed initiatives to expand oil exploration and production in Nevada.

The U.S. Geological Survey estimates that federal lands in Nevada contain approximately 1.4 billion barrels of undiscovered, technically recoverable oil resources. If more Nevada crude comes to market, Eagle Springs could refine suitable barrels in-state and grow with Nevada’s oil industry.

Separately, Sky Quarry continues discussions regarding its previously announced farm-in opportunity at PR Spring and potential collaboration involving its 7-megawatt power generation capacity. The Company expects to provide updates as those discussions progress.

About Sky Quarry Inc.

Sky Quarry Inc. is an energy infrastructure company focused on domestic refining and resource development. Through its wholly owned subsidiary, Foreland Refining Corporation, the Company operates the Eagle Springs Refinery near Ely, Nevada, which produces diesel, vacuum gas oil, naphtha and liquid paving asphalt. Sky Quarry is also developing its PR Spring facility in Utah to recover hydrocarbons and other marketable materials from waste asphalt shingles and oil-bearing resources.

For more information, visit Sky Quarry’s corporate website at https://skyquarry.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “expect,” “anticipate,” “believe,” “intend,” “plan,” “will,” “may,” “should,” “estimate,” “potential,” “project,” “continue,” and similar expressions, or the negative of such terms. These forward-looking statements include, but are not limited to, statements regarding the refinery’s operating ramp-up, the availability of crude oil feedstock, the Company’s ability to sustain operations, nameplate capacity, regional refining capacity and market demand, and potential Nevada oil development and PR Spring opportunities. These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in or implied by the forward-looking statements. Such risks and uncertainties include, but are not limited to: risks related to the Company’s ability to ramp up and sustain refinery operations; fluctuations in crude oil prices, refined product prices, and refining margins; the Company’s ability to obtain adequate supplies of crude oil feedstock at competitive prices; regional competition from other refineries and fuel suppliers; changes in demand for refined products in the Western United States; the Company’s ability to attract and retain customers; risks associated with the operation of refining facilities, including equipment failures, unplanned downtime, and regulatory compliance requirements; the Company’s ability to manage costs and maintain operational efficiency; the availability and cost of labor, equipment, and materials; changes in environmental, health, safety, or other regulations affecting the refining industry; the Company’s ability to maintain adequate liquidity and working capital to support operations; general economic conditions, including inflation, interest rates, and recessionary pressures; and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The forward-looking statements contained in this press release are made as of the date hereof, and except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.

Investor Relations Contact

Sky Quarry Inc. Email: ir@skyquarry.com

Approximately 400 core samples submitted for assay as ESGold advances its 5,000-metre drill program

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) (the “Company” or “ESGold”) is pleased to provide an update on its 2026 diamond drilling program at the Montauban Project, located approximately 80 kilometres west of Québec City, Québec.

As of September 15, 2026, ESGold had advanced 19 drill holes for a cumulative total of approximately 2,030 metres, marking an important milestone in the Company’s 2026 exploration program.

Importantly, drilling continues to intersect alteration, quartz-carbonate veining and locally sulphide-bearing intervals within the geological environment associated with the historic Montauban mineralized system.

Observed sulphides to date include pyrite, pyrrhotite and galena, locally occurring within or adjacent to quartz-carbonate veins, altered gneissic units and structurally affected intervals.

Approximately 400 core samples have now been submitted to SGS Laboratories in Val-d’Or for analysis, with assay results pending.

“Passing 2,000 metres is an important milestone in our 5,000-metre program, but what is particularly encouraging for us is what we continue to see in the core,” said Gordon Robb, CEO and Director of ESGold. “We are repeatedly encountering alteration, quartz-carbonate veining and sulphide-bearing intervals within the geological environment associated with the historic Montauban mineralized system.

“With approximately 400 samples now at SGS Laboratories in Val-d’Or, the next step is determining the significance of what we are seeing. At the same time, drilling continues as we test how this system may extend beyond the historic workings and at depth. Every hole is giving us more information to integrate with the historic mine data, ANT geophysics and our 3D geological model.”

Highlights

• ESGold has completed approximately 2,030 metres across 19 drill holes as part of its planned 5,000-metre 2026 diamond drilling program.
• Drilling has repeatedly encountered alteration, quartz-carbonate veining and locally sulphide-bearing intervals within the geological environment surrounding the historic Montauban mineralized system.
• Observed sulphides include pyrite, pyrrhotite and galena, locally associated with quartz-carbonate veining, alteration and structurally affected intervals.
• Approximately 400 core samples have been submitted to SGS Laboratories in Val-d’Or for assay.
• Nine drill holes have intersected historic underground workings or voids, providing valuable geological control for reconciling modern drilling with the geometry of the former mine.
• Drilling remains ongoing as ESGold evaluates the potential continuation of the Montauban system outside and below the historic mine workings.

Sulphide-Bearing Intervals Observed in Drill Core

Core logging completed to date has identified repeated sequences of amphibolite and quartz-feldspar, biotite- and muscovite-bearing gneisses together with zones of silicification, chlorite-sericite alteration, deformation and quartz-carbonate veining.

Sulphides have been observed within or adjacent to quartz-carbonate veins, altered gneissic units and structurally affected intervals in holes including MM-26-03, MM-26-04 and MM-26-11.

These observations are significant from a geological targeting perspective because they provide direct information on the alteration, structural features and lithological contacts associated with the historic Montauban mineralized environment.

Visual observations are not necessarily indicative of economic mineralization and laboratory assays are required to determine metal grades.

Figure 1: 2026 drill-hole locations across the historic Montauban mine area

Figure 2: A) Hole MM-26-03, box 5 (20.42m to 24.68m); B) MM-26-04, boxes 7 and 8 (27m to 35m); C) MM-26-11, box 5 (23m to 27m); D) MM-26-11, box 23 (101.60m to 105.85m). Assay results are pending.

Testing Beyond the Historic Mine

The 2026 drill program is designed first to confirm the presence and continuity of mineralization along the main mineralized structure, and then to extend beyond the historical underground workings to test additional targets and potential extensions of the system. The drilling program is testing the geological interpretation developed from historical mine information, ESGold’s drillhole compilation, ANT surveys by CAUR Technologies, and 3D geological modelling by Geomatic World.

Each new drill hole provides direct geological information that can be incorporated into the evolving 3D model and compared with features interpreted through the ANT surveys.

Assays and Next Steps

Core logging, cutting and sampling are continuing as drilling advances toward the planned 5,000 metres.

Approximately 400 samples have been submitted to SGS Laboratories in Val-d’Or for analysis. Assay results will be reported as they are received, reviewed and validated under the Company’s QA/QC procedures.

The Company will use the combined geological, structural and assay information to refine the integrated 3D geological model, correlate new drilling with historical mineralized zones and underground workings, and prioritize additional shallow and deeper targets designed to test potential extensions of the Montauban system.

Next Steps

Core logging and sampling are continuing as the drilling program advances.

As part of this first exploration phase, the entire drill core is being sampled and analyzed to ensure that the maximum amount of geological and geochemical information is collected.

The Company intends to use the combined geological, structural and assay information to:

• refine the integrated 3D geological model;
• evaluate the relationship between mineralization, lithological contacts, alteration and structural features;
• prioritize additional shallow and deeper drill targets designed to test potential extensions of the Montauban system.

Laboratory assay results will be reported once received, reviewed and validated in accordance with the Qualified Person’s QA/QC procedures.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Merouane Rachidi, Ph.D., P.Geo., an independent Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About ESGold Corp.

ESGold Corp. (CSE: ESAU | OTCQB: ESAUF | FSE: Z7D) is a fully permitted, fully funded, pre-production mining company advancing a scalable clean mining model across North America. The Company’s flagship Montauban Gold-Silver Project in Québec is under construction. With a dual-track strategy of cash flow today and discovery tomorrow, ESGold is building a platform for clean, sustainable growth and long-term shareholder value.

For more information, please contact ESGold Corp. at 1-888-370-1059 or visit esgold.com for additional resources, including a French version of this press release, past news releases, a 3D model of the Montauban processing plant, media interviews, and opinion-editorial pieces.

Stay connected by following us on X (formerly Twitter), LinkedIn, and joining our Telegram channel.

For further information on the Company please contact:
Email: ir@esgold.com or info@esgold.com or gordon@esgold.com
Phone: 604-885-1348 or 1-888-370-1059 or 250-217-2321

On behalf of the Board of Directors of ESGold Corp.
Gordon Robb
Chief Executive Officer & Director

Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements regarding the ANT survey, the 3D model, and current and future exploration activities and potential. Forward-looking information is based on reasonable assumptions believed to be current but involves known and unknown risks and uncertainties that may cause actual results to differ materially. Historical data referenced herein is not current, has not been independently verified by ESGold, and should not be relied upon for investment decisions. ESGold disclaims any obligation to update or revise forward-looking information except as required by law.

These forward-looking statements reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include, among other things: a possible drill program and results therefrom and exploration activities at the Montauban Project, the ANT-based 3D geological model, its results and interpretation of the same, conditions in general economic and financial markets; accuracy of assay results; geological interpretations from drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; the historical basis for current estimates of potential quantities and grades of target zones; the availability of skilled labour and no labour related disruptions at any of the Company’s operations; no unplanned delays or interruptions in scheduled activities; all necessary permits, licenses and regulatory approvals for operations are received in a timely manner; the ability to secure and maintain title and ownership to properties and the surface rights necessary for operations; and the Company’s ability to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive.

The Company cautions the reader that forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements contained in this news release and the Company has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; general market and industry conditions; and those factors identified under the caption “Risk Factors” in the Company’s continuous disclosure documents filed on SEDAR+ at www.sedarplus.ca.

Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/5d89a957-9b14-4d79-840e-cc3ad60b2f6a
https://www.globenewswire.com/NewsRoom/AttachmentNg/4131a9b9-966b-412c-810b-4151d3176e2a

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3 | OTCQB: GXPLF), is pleased to announce the completion of a 2026 summer exploration program (the “Program”) at the Hook-Carter Uranium Project (“Hook-Carter”, or the “Project”) located in the southwestern Athabasca Basin region of Saskatchewan, Canada. The Project is owned 25% by Greenridge and 75% by Denison Mines Corp. (“Denison”), with Denison acting as operator of exploration. Hook-Carter is host to the interpreted northeastern strike extensions of parallel structural trends, including the Derkson Corridor and the prolific Patterson Lake Corridor (“PLC”), along which multiple uranium deposits and showings have been discovered to the southwest of the Project.

Highlights of the Hook-Carter 2026 Exploration Program

• Denison and Greenridge carried out thirteen (13) lines of Fixed Loop Electromagnetic (“FLEM”) surveying totaling 15.85 line-kilometres on two (2) ground loops, with readings taken at fifty (50) metre station spacings on the Derkson Corridor, where summer ground conditions allowed access to the area of interest (see Figure 1);
• Concurrent with the FLEM survey, a geochemical sampling crew collected four hundred twenty-nine (429) soil samples at fifty (50) metre intervals on thirteen (13) lines over the 19.5 line-km Derkson Corridor grid. The soil samples were submitted to Activation Laboratories Ltd. (“Actlabs”) in Ancaster, Ontario for ICP-OES and ICP-MS analyses by 4-acid digestion and INAA, and for spatiotemporal geochemical hydrocarbons (“SGH”) soil analysis.

Figure 1 – Hook-Carter Summer 2026 Exploration Grids Over Airborne ZTEM Conductivity

• A light detection and ranging (“LiDAR”) survey was flown over the PLC and Derkson Corridors using an exSWARM LiDAR high resolution Digital Elevation Model survey with 0.5 metre cells over a 44 km² area. The LiDAR survey will provide precise, three-dimensional information about the surface of the Project, which can assist to outline structural features such as the muted expression of strike-slip faults, linear rifts, and depressions.

Russell Starr, Chief Executive Officer of Greenridge stated: “Our 2026 summer Program at Hook-Carter is an important step for target development at Hook-Carter. The results of this work are expected to provide a higher focus for drill hole targeting along the Derkson Corridor, which will support potential drilling programs in 2027 and beyond.” 

About the Derkson Corridor

In 1978, drill hole DER-04 collared within the Derkson Corridor intersected 0.24% U₃O₈ over 2.5 metres from 120.5 to 122.5 metres, approximately 4.25 kilometres to the south of the current boundary of the Project (see Figure 2).

Figure 2 – Uranium Deposits and Occurrences Proximal to the Hook-Carter Project

The uranium discovery in hole DER-04 sparked a series of drill campaigns by the Saskatchewan Mining and Development Corporation (“SMDC”, a predecessor company of Cameco Corporation) to locate additional mineralization, but no significant uranium occurrences were found in the immediate area of hole DER-04. Denison and Greenridge consider that the northern extent of the Derkson Corridor could be highly-prospective for hosting uranium mineralization, as is evidenced by a 2004 study of historical Derkson Corridor drill core carried out by UEM Inc. (a joint venture company held by Cameco Corporation and a predecessor of Orano Canada) that concluded: “…in summary, the drill holes which display the most encouraging combination of prospective features…include DDHs DER-23, DER-09 and DER-13. Significantly, DDH’s DER-23 and DER-09 are the most northerly of the DER holes. There has been only a limited number of prior drill tests…to the north of DDH DER-23.”¹ The site of drill hole DER-23 lies approximately 2.75 kilometres south of the current Hook-Carter property boundary.

About the Hook-Carter Geochemical Survey

SGH is a method of geochemical exploration that detects one hundred sixty-two (162) specific hydrocarbon compounds presumed to have migrated from a mineralized body in the subsurface through rock cover and overburden and have been adsorbed on the surficial soils. SGH laboratory analyses detect these hydrocarbons as a method of identifying the location of buried, or “blind”, mineralized bodies. Recent research has shown that there are relationships between specific commodities and SGH compound classes that can provide a “hydrocarbon fingerprint” for metals such as uranium.²

About Hook-Carter

Hook-Carter consists of eleven (11) claims covering 25,115 hectares and is located in the southwest corner of the Athabasca Basin approximately one hundred forty-seven (147) kilometres northeast of La Loche, SK. Hook-Carter is interpreted to host the northeastern strike extension of the PLC, which hosts NexGen Energy’s Arrow uranium deposit (and a potential expansion of the width of the PLC with the recently discovered Patterson Corridor East zone), Paladin Energy Limited’s Triple R uranium deposit and its new discovery known as the Atlas occurrence, and Purepoint Uranium Group’s Spitfire, Hornet, and Dragon zones in a joint venture with Cameco Corporation and Orano Canada (see Figure 2). The Project also overlies the interpreted strike extensions of the Carter and Derkson corridors, each of which represent highly prospective and under-explored structural corridors.

The 2026 summer exploration Program was based from a permitted temporary work camp located on the Project. Denison, as operator of exploration, is committed to collaborating with Indigenous peoples and communities to build long-term, respectful, trusting, and mutually beneficial relationships and aspires to avoid any adverse impacts of Denison’s activities and operations, which intentions are expressed in Denison’s Indigenous Peoples Policy.

Details of the Hook-Carter Joint Venture Agreement

In October 2016, ALX Resources Corp. (“ALX”) and Denison entered into a purchase agreement whereby ALX sold an 80% interest in the Project in exchange for 7.5 million common shares in the capital of Denison. ALX retained a 20% interest in Hook-Carter, and Denison agreed to fund ALX’s share of the first $12.0 million of expenditures. On November 15, 2019, ALX and Denison executed a written acknowledgement with respect to the deemed formation of a joint venture between them upon Denison’s completion of a requirement to solely fund a minimum of $3.0 million of project expenditures within an initial 36-month funding period. From 2016 to 2023, Denison’s exploration expenditures at Hook-Carter totaled approximately $7.08 million, including the completion of surface and airborne geophysical programs, as well as nearly 12,000 metres of diamond drilling.

In May 2024, the Hook-Carter joint venture was amended whereby ALX could increase its ownership interest in the Project from 20% to 25% by funding the next $3.0 million of exploration at the Project by November 2026. On December 30, 2024, ALX was acquired by Greenridge by way of a court-approved Plan of Arrangement and Greenridge assumed ALX’s ownership interest and its funding obligations in the amended Hook-Carter joint venture. During the 1^st Quarter and 2^nd Quarter 2026, Greenridge met the $3.0 million expenditure and has increased its cumulative ownership percentage in the Hook-Carter joint venture to 25%.

Statement of Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Sean Hillacre, M.Sc., P. Geo., a geological consultant to the Company and a Qualified Person for Greenridge as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Hillacre has examined information regarding the historical and current exploration at Hook-Carter, which includes a high-level review of the historical sampling, analytical, and procedures underlying the information and opinions contained herein.

Management cautions that historical results collected and reported by operators unrelated to Greenridge have not been verified nor confirmed by its Qualified Person; however, the historical results create a scientific basis for ongoing work in at Hook-Carter. Management further cautions that historical results, discoveries and published resource estimates on adjacent or nearby mineral properties, or other properties located within the Athabasca Basin, whether in reference to stated current resource estimates or historical resource estimates, are not necessarily indicative of the results that may be achieved on the Project.

About Greenridge Exploration Inc.

Greenridge is a mineral exploration company dedicated to creating shareholder value through the acquisition, exploration and development of critical mineral projects in Canada. The Company owns or has interests in 19 projects and additional claims covering approximately 229,842 hectares with considerable exposure to potential uranium, gold and nickel discoveries. The Company is led by an experienced management team and board of directors with significant expertise in capital raising and advancing mining projects.

Greenridge has one of the largest uranium property portfolios in Canada consisting of 12 projects and additional prospective claims covering approximately 167,800 hectares. The Company has opportunities to realize value in a further seven strategic metals projects which include gold, and nickel, copper and cobalt exploration properties totalling approximately 62,042 hectares. Project highlights include:

• The Black Lake Uranium Project, located in the NE Athabasca Basin, (40% Greenridge, 50.43% Uranium Energy Corp., 8.57% Orano Canada) saw a 2004 discovery hole (BL-18) return 0.69% U₃O₈ over 4.4m.³
• The Hook-Carter Uranium Project (25% Greenridge, 75% Denison Mines Corp.) is strategically located in the southwest Margin of the Athabasca Basin, sitting ~13km from NexGen Energy Ltd.’s Arrow deposit and ~20 km from Paladin Energy’s Triple R deposit.
• The Gibbons Creek Uranium Project hosts high-grade uraniferous boulders located in 2013, with grades of up to 4.28% U₃O₈ ⁴, and the McKenzie Lake project saw a 2023 prospecting program return three samples which included 844 ppm U-total (0.101% U₃O₈), 273 ppm U-total, and 259 ppm U-total.⁵
• The Nut Lake Uranium Project located in the Thelon Basin includes historical drilling which intersected up to 9 ft of 0.69% U₃O₈ including 4.90% U₃O₈ over 1ft from 8 ft depth.⁶   In 2024, Greenridge’s prospecting program located a float sample that returned 31.13% U₃O₈, sourced from the Tundra Showing.⁷
• The Firebird Nickel Project has seen two drill programs (7 holes totaling 1,339 m), where hole FN20-002 intersected 23.8 m of 0.36% Ni and 0.09% Cu, including 10.6 m of 0.55% Ni and 0.14% Cu.⁸

The Company has strategic partnerships, which include uranium exploration properties being operated and advanced by Denison Mines Corp. and Uranium Energy Corp. The Company’s management team, board of directors, and technical team bring significant expertise in capital raising and advancing mining projects and is poised to attract new investors and raise future capital.

References:

1 – Saskatchewan Mineral Assessment Database, Report #74F11-0033, 2005.
2 – “Finding Deeply Buried Deposits Using Geochemistry”. In: Geochemistry: Exploration, Environment, Analysis, 2004, Vol. 4, No. 1; Cameron, E.M, et al.
3 – Black Lake: UEX Corporation News Release dated October 12, 2004.
4 – Gibbons Creek: Lakeland Resources Inc. News Release dated January 8, 2014.
5– McKenzie Lake: ALX Resources Corp. New Release dated November 7, 2023.
6 – Nut Lake: 1979 Assessment Report (number 81075) by Pan Ocean Oil Ltd.
7 – Nut Lake: Greenridge Exploration Inc. News Release dated February 19, 2024.
8 – Firebird Nickel: ALX Resources Corp. New Release dated April 15, 2020.

On Behalf of the Board of Directors of Greenridge

Russell Starr
Chief Executive Officer, Director
Telephone: +1 (778) 897-3388
Email: info@greenridge-exploration.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Greenridge, future growth potential for Greenridge and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, nickel, copper, gold, cobalt and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Greenridge’s ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company’s objectives, goals, or future plans with respect to the Project; further exploration work on the Project in the future; anticipated benefits of conducting the Program; the Company’s objectives, goals, or future plans with respect to any of its projects; further exploration work on its projects in the future. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, nickel, copper, gold, cobalt and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/3c995a0c-ac2b-48a3-bf65-00bbae402822
https://www.globenewswire.com/NewsRoom/AttachmentNg/ba599a4e-f10a-4161-b4d8-0c6a476cc71a

– Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients –

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer (NCT07562152) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

Poster Presentation Details:
Title: MAPKeeper-301: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus Standard Gemcitabine and nab-Paclitaxel for Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Lead Author: Eileen M. O’Reilly, MD, Memorial Sloan Kettering Cancer Center
Session Title: Pancreatic cancer
Poster Number: 3189TiP
Date and Time: Sunday, October 25, 2026, 12:00-12:45 pm CET

Full abstracts will be published on the ESMO website on October 19, 2026, at 00:05 CEST. Following presentation, the poster will be available on the publications section of Immuneering’s website at https://immuneering.com/publications.

About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.

Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer including modified Gemcitabine/nab-paclitaxel (mGnP), and its potential to reduce tumor volume and preserve body mass in pancreatic cancer; the timing and content of planned upcoming presentations; and the potential ability of the three design mechanisms of atebimetinib to shrink tumors durably, improve overall survival and overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Contact:
Laurence Watts
New Street Investor Relations
laurence@newstreetir.com

Media Contact:
David Caouette
dcaouette@immuneering.com

MONTREAL, Sept. 24, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) is pleased to provide an update on its expansion within Senegal and Ecuador and on its Peruvian operations.

Key Highlights

Ecuador

• Overall plant rehabilitation is 65% complete and on schedule for first ore feed in Q4-2026.
• Upgrade of the main milling equipment is complete and the crushing area is over 85% complete. 
• Pre-commissioning activities are planned in October, initially in the main process plant area:
  • Tests have been conducted on the ball mill, which has been operated without loads.
  • Sourcing of 500 tonnes of sterile rock is underway for use in initial commissioning.
• First ore feed is scheduled in October, followed by commissioning through Q4-2026. 
• Initial gold pour is targeted for Q4-2026, subject to successful completion of plant rehabilitation and commissioning.

Senegal

• All commissioning activities are complete, and the 50-tpd plant is being ramped up.
• Additional stock has been sourced from new suppliers.
• Preparations are in place for the inaugural gold pour.
• Initial plant operator and other internal positions are being filled.

Peru

• Ore inventory reduction is ongoing and is expected to reach 75% of the historical average by quarter-end.

Daniel Misiano, President & CEO of Dynacor, commented: “Congrats to the Dynacor team for successful execution on our two expansion projects, which will add materially to our 2027 production. With all critical aspects advancing as planned, the priority is now to complete rehabilitation of the Svetlana plant and begin commissioning. We look forward to providing more visibility on Africa’s potential for value creation through our ramp-up of production in Senegal.

Moreover, reduction of ore inventory levels is being accelerated in Peru. We are on track for a strong finish to the year with expansion milestones and operations expected to further enhance stakeholder value.”

Figure 1 – Svetlana’s Ball Mill has been Tested

Advancing Ecuador Plant Upgrade to Plan

Dynacor’s rehabilitation of the 1,500-tpd Svetlana processing plant continues to progress to plan, and first ore feed and gold pour remain on track for Q4-2026:

• The project is 65% complete, on time and on budget. Most major equipment is now on site.
  • On budget – As of August 30, 2026, US$9.5 million had been spent of the US$22-$25 million projected capital expenditure for 2026…
• Crushing circuit – Rehabilitation of the crushing circuit is 85% complete, the mill feed almost 65% complete, and fabrication of the apron support has commenced.
• Milling area – Rehabilitation of the ball mill and supporting infrastructure is fully complete.
• Electrical / power systems – Installation of the electrical cable infrastructure is well advanced. Dynacor has signed an agreement with CNEL EP (Ecuador’s national utility) to secure a 6-MW grid connection. The connection will feed into the Svetlana substation to supply mainly hydro-backed renewable energy to power the plant.
• Leaching area – Rehabilitation of the leaching infrastructure is some 70% complete.
• Operational readiness – Operational readiness activities and hiring are ramping up, in line with plan.
• Tailings – Following repair of its geomembrane, the working tailings storage facility is expected to be operational at month-end.
• Permitting progress – Dynacor’s application for a commercialisation permit has been approved by ARCOM, Ecuador’s mining regulatory agency. Approval from the MAE (Ministry of Environment and Energy) is pending and expected in Q4-2026.

Figure 2: Tank Sampling at Galam in Senegal

About Dynacor

Dynacor Group is an ore processing company dedicated to producing gold sourced from artisanal miners. Since its establishment in 1996, Dynacor has pioneered a responsible mineral supply chain with stringent traceability and audit standards for the fast-growing artisanal mining industry. By focusing on formalized miners, the Canadian company offers a win-win approach for governments and miners globally. Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru. The company is expanding to West Africa and within Latin America.

The premium paid by luxury jewellers for Dynacor’s PX Impact® gold goes to Fidamar Foundation, an NGO that mainly invests in health and education projects for artisanal mining communities in Peru. Visit www.dynacor.com for more information.

Forward-Looking Information

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Contact:

For more information, please contact:

Ruth Hanna
Director, Investor Relations
T: 514-393-9000 #236
E: investors@dynacor.com
Website: https://dynacor.com

Renmark Financial Communications Inc.
Bettina Filippone
T: (416) 644-2020 or (212) 812-7680
E: bfilippone@renmarkfinancial.com
Website: www.renmarkfinancial.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b1121997-1642-4599-b9bc-076b68c13a96
https://www.globenewswire.com/NewsRoom/AttachmentNg/e5ce501d-f52d-43de-9071-15814adb3186

Initial $1,000,000 USD Investment with Anticipated Follow-on Investments From a Leading Institutional Investor

Ninety-Day Commitments on Track

WINTER PARK, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, today announced that an institutional investment manager has launched an investment strategy using GLDY, Streamex’s gold-backed, yield-bearing tokenized asset, as the long leg of a gold-denominated delta-neutral trade. A leading institutional investor will allocate an initial $1 million to the strategy with anticipation to scale beyond with follow on investments as the strategy demonstrates its performance. Streamex views strategies of this kind as a powerful new channel for growing GLDY assets under management. Separately, the ninety-day commitments Streamex set when it reported second quarter earnings in mid-August are on track.

Highlights

• Institutional capital deployed into a GLDY-based strategy: a leading institutional investor will allocate an initial $1,000,000 USD to an investment strategy using GLDY as its long asset. Streamex anticipates the allocation to scale beyond that with follow on investments as the strategy demonstrates its performance.
• A powerful new channel for GLDY AUM growth: the strategy, run by an institutional investment manager, uses GLDY as the long-gold leg of its trade, so as the strategy scales, GLDY assets under management grow in tandem.
• Ninety-day commitments on track: converting the first institutional allocations into GLDY was the top objective Streamex set for itself in August, and it has now been met.

Henry McPhie, Co-Founder & Chief Executive Officer of Streamex, said:

“During our second quarter earnings call, we told investors what to hold us to over the following ninety days, and converting institutional allocations into GLDY was at the top of that list. Now that happened. An institutional investment manager has launched a strategy built around GLDY, and a separate leading institutional investor has deployed an initial $1 million USD into it. As the strategy performs, that allocation can scale from the same investor. We believe that the launch of the strategy and investment anchoring it from a large outside investor brings real credibility to the platform we have built for GLDY.”

Progress Against the Ninety-Day Commitments Set in Mid-August 2026

Commitment	Status as of September 24, 2026
Convert the institutional allocations into GLDY	Met. An initial $1 million was allocated to an investment strategy that holds GLDY as its long asset. Streamex anticipates the allocation to scale beyond with follow on investments as the strategy demonstrates performance; amounts beyond the initial deployment are at the investor’s discretion.
Onboard the institutional partners as holders, not indications of interest	Met. An institutional manager acquires GLDY as capital is deployed under the strategy.
Launch initial liquidity bootstrapping for GLDC	In progress, on timeline.
Launch GLDC once initial liquidity bootstrapping is complete	Sequenced to follow completion of bootstrapping.
Complete the Equity Trust IRA integration	In progress.
Keep attesting and distributing, monthly and without interruption	Ongoing. The sixth consecutive monthly GLDY yield distribution was paid in September 2026, with reserves viewable via the Chainlink Proof of Reserves oracle.

About Streamex Corp.

Streamex Corp. (NASDAQ: STEX) is a technology and infrastructure company focused on the tokenization and digitalization of commodity real-world assets. Streamex delivers institutional-grade solutions that bridge traditional finance and blockchain-enabled markets through secure, regulated, and yield-bearing financial instruments.

For more information, visit www.streamex.com.

Important Disclosure
This press release is issued by Streamex Corp. concerning developments in its own business. It is not an offer to sell or a solicitation of an offer to buy any security, including any interest in any fund or investment strategy referenced herein, and it is not intended to advertise, promote, or solicit investment in any fund. No information contained herein should be construed as a recommendation to invest in any fund or trading or investment strategy.

Streamex is not a placement agent, distributor, solicitor, or agent for the investor referenced in this release, its manager, or any fund, and receives no compensation based on capital raised by any such fund. References to the strategy are provided solely as context for Streamex’s commercial relationship with the investor and its expected effect on GLDY assets under management. This release is not a channel for fund-related inquiries, and Streamex will not respond to or forward any such inquiries.

Capital commitment. The commitment described herein represents an indication of capital to be deployed and remains subject to execution of definitive documentation, satisfaction of conditions, and funding. There can be no assurance that it will be funded in whole or in part, or that any particular amount of GLDY will be acquired. The reference to the commitments the investor has made are provided with its consent.

Nothing in this release constitutes investment, legal, tax, or accounting advice. GLDY is offered by Streamex Ltd. pursuant to applicable exemptions from registration and is available only to eligible investors; this release does not constitute an offer of GLDY. The targeted 3.5% annualized GLDY yield is a target, is not guaranteed, and is subject to the risks of the Company’s gold leasing program, including counterparty default.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. securities laws, including statements regarding the institutional capital commitment described herein, the funding and deployment of that commitment, anticipated growth in GLDY assets under management and related management fee income, including management’s expectations regarding broader institutional adoption of GLDY, statements regarding Streamex’s progress against and expected completion of the objectives described on its second quarter 2026 earnings call, the continued payment of the 3.5% targeted annualized yield on GLDY and the continued availability of liquidity and settlement characteristics for GLDY, management’s beliefs regarding the significance of the first institutional order for the Company’s tokenization platform, and Streamex’s business strategy and future growth. There can be no assurance that the capital commitment described will be funded in whole or in part, that any particular amount of GLDY will be acquired, or that GLDY assets under management will grow by any particular amount. These statements are based on current expectations and assumptions subject to risks and uncertainties, many of which are beyond Streamex’s control, and actual results may differ materially. Factors that could cause such differences include, among others, market conditions, gold price volatility, funding rate volatility in derivatives markets, the actions and timing of third parties, including institutional allocators, custodians, trading venues, and the strategy’s manager, the Company’s ability to continue to generate and distribute the targeted yield through its gold leasing program and to maintain current liquidity and settlement characteristics for GLDY, regulatory developments, and macroeconomic factors affecting digital asset and commodity markets. A discussion of these and other factors is set forth in Streamex’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or updated by Streamex’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Streamex undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Contacts Streamex Press & Investor Relations
Laura Kiernan Head of Investor Relations IR@streamex.com | laura@streamex.com	Henry McPhie Chief Executive Officer, Streamex Corp. www.streamex.com | X.com/streamex

Agreement would expand the companies’ genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel

ARLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Kala Bio, Inc. (Nasdaq: KALA) (“Kala”) and Virotek Inc. (“Virotek”) today announced that they have signed a non-binding letter of intent (the “LOI”) with a U.S. DNA testing platform under which the platform would resell Virotek’s selected suite of genomic testing products. The mechanics of the commercial and economic terms are being finalized. Assuming negotiations are completed, the companies expect to name the reselling parties in the coming weeks.

The LOI follows the exclusive U.S. distribution and reseller agreement between Kala and Virotek announced on September 3, 2026. Under that agreement, Kala markets and distributes Virotek’s genetic testing and screening program in the United States while Virotek operates the laboratory infrastructure, kit supply, specimen processing, and clinical reporting. Although the initial contract with Virotek is for ophthalmology, KALA facilitated the introduction to the potential reseller and will therefore benefit economically if the deal closes, through a profit-split or commission-based structure, since Virotek will shoulder most of the logistics to fulfill orders.

For Virotek, the proposed arrangement would expand distribution of selected genetic testing products through an additional U.S. channel. For Kala, it would represent the first reseller relationship facilitated under the Virotek collaboration beyond ophthalmology. Any expansion remains subject to definitive agreements and the applicable scope of the parties’ existing agreements.

The companies believe the proposed arrangement may create an additional channel for appropriately ordered genetic testing across a range of clinical applications beyond ophthalmology. Virotek will continue to maintain responsibility for its laboratory processes, clinical reporting, quality standards, and applicable regulatory and compliance requirements.

The LOI is non-binding, except for certain limited provisions. The proposed arrangement remains subject, among other things, to finalizing the economic terms, negotiating and executing definitive agreements, and other customary conditions. There can be no assurance that definitive agreements will be reached on the contemplated terms, if at all, that the reselling parties will be named, or that the arrangement will generate revenue. Kala has not established, and this release does not contain, any revenue projection.

“This is the step that takes our genetic testing program beyond ophthalmology and into the wider market. We are still finalizing the economics, and there is no guarantee we complete them, but we believe this relationship puts Kala on a path to realizing revenue from the program. Just as important, it is a marker of what we are building: an AI- health-centred, biotech-oriented company that grows through its verticals and delivers long-term value to shareholders,” said Avi Minkowitz, Chief Executive Officer of Kala.

“This proposed arrangement expands the reach of Virotek’s clinical genomics platform through an additional commercial channel while preserving the standards that define our offering. As we broaden our commercial relationships, our priority remains clinical quality, scientific rigor and the responsible delivery of Virotek’s testing services,” said Dr. Saeid Babaei, Chairman and Chief Executive Officer of Virotek.

About Kala Bio, Inc. (NASDAQ: KALA)
KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business that deploys secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.

Through its exclusive worldwide license for Younet’s Researgency AI research platform, Kala intends to serve as the biotechnology industry’s dedicated AI infrastructure partner, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.

Kala believes the future of biomedical innovation is in agentic systems.

For more information, visit www.kalarx.com and Researgency.ai

About Virotek

Virotek Inc. is a U.S. precision health and clinical genomics company offering products and services to healthcare providers and organizations across the continuum of care, from preventive risk assessment and early cancer detection to personalized treatment guidance, delivered through an integrated clinical genomics platform. Virotek’s testing services are supported by its laboratory, quality, clinical reporting, and compliance infrastructure. For more information, visit Virotek.io.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategic initiative to build an AI infrastructure platform for the biotechnology industry; plans to develop and deploy the Researgency AI platform both internally and to external clients; expectations regarding the potential benefits of AI-driven analytical tools; plans to reassess historical datasets and identify new therapeutic indications; expectations regarding the AI drug discovery market and industry trends; expectations regarding the Company’s ability to generate recurring platform revenue; plans regarding potential partnerships, client deployments, or technology licensing opportunities; expectations regarding the Company’s competitive position and the differentiation of its on-premises deployment model; the potential exercise of development continuation or renewal options under the Agreement; and other statements that are not historical facts. It also includes statements regarding the proposed distribution partnership with Virotek, including the negotiation and execution of definitive agreements and the anticipated benefits and timing thereof.

The Company used words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions to identify these forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from those expressed or implied by such statements. Important factors that could cause such differences include, but are not limited to: risks that AI technologies may not produce expected results in drug discovery or development; risks related to the development, deployment, and performance of the Researgency platform; risks that the Company may not successfully attract or retain external platform clients; risks that the platform-as-a-service business model may not generate anticipated revenues; risks that the Company’s product candidates may not be successfully developed or commercialized; risks related to the Company’s limited cash resources and ability to continue as a going concern; risks that the third-party information contained herein was not accurate at the time it was published and/or does not accurately predict the future; risks related to the Company’s ability to raise future capital and the possibility that market conditions may limit the Company’s ability to raise capital on favorable terms; risks related to the Company’s ability to regain compliance with Nasdaq listing requirements; competition from larger, better-resourced companies including major technology and pharmaceutical companies; dependence on key personnel and third-party technology providers; the accuracy of third-party market forecasts and projections cited herein; risks that the Company may elect not to expand or continue its deployment of the Researgency platform beyond the initial term; risks that Younet may not perform its obligations under the Agreement; and other risks detailed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K as they may be revised in the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts:

Avi Minkowitz
Chief Executive Officer, KALA BIO, Inc.
am@kalarx.com
www.kalarx.com | www.Researgency.ai

Dr. Saeid Babaei
Chairman and Chief Executive Officer, Virotek Inc.
info@virotek.io

BERKELEY, CA, Sept. 24, 2026 (GLOBE NEWSWIRE) — Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies today announced that the Company has received a positive decision from GMED regarding certification of its quality management system to ISO 13485. GMED is a notified body designated under the European Union Medical Device Regulation (MDR). The Company continues to work with GMED toward completion of the remaining applicable MDR conformity assessment activities for the Lumee® Oxygen Platform. Successful completion of these activities would support issuance of the applicable MDR certificate and the Company’s subsequent CE marking of the Lumee Oxygen Platform. The CE mark signifies that a product sold within the 27 EU member states meets high safety, health and environmental protection standards.

“We are pleased with the progress we have made in strengthening our quality management system, responding to GMED’s requirements and, importantly, receiving a positive decision regarding ISO 13485 certification,” said Ben Hwang, Ph.D., President of Profusa. “This represents a significant milestone for Profusa and reflects the outstanding work our team has undertaken to address GMED’s observations and advance our path toward completion of MDR conformity assessment for the Lumee Oxygen Platform.”

While the Company has made progress in its conformity assessment activities, there can be no assurance regarding the timing or outcome of GMED’s remaining assessment activities or the timing of CE marking for the Lumee Oxygen Platform.

The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through Profusa’s proprietary tissue-integrated biosensor technology. The platform is intended to provide clinicians with objective tissue perfusion data that may support treatment decision-making and patient monitoring.

About Profusa

Based in Berkeley, California, Profusa is a digital health company developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on pioneering next-generation biosensor technologies. Profusa previously announced the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of certain conditions, to acquire G3 Vision Labs, Inc. and its subsidiaries (“G3″). Upon option exercising, the combined company is expected to operate as a public diagnostics company.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea, and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa, including statements regarding the proposed acquisition of G3, and Profusa’s strategic plans. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements including, without limitation, risks related to the Company’s planned European and U.S. product launches, the risk that such product launches may not result in revenue at the levels anticipated, the risk that customer demand may be less than expected, and risks relating to the Company’s withdrawal of the Registration Statement and conducting a smaller offering of its securities. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described more fully in the Company’s public filings made by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Investor and Media Contact:

info@coreir.com
212-655-0924